Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.
about
Specificity of lipoprotein-associated phospholipase A(2) toward oxidized phosphatidylserines: liquid chromatography-electrospray ionization mass spectrometry characterization of products and computer modeling of interactionsPhospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionIdentification of distant drug off-targets by direct superposition of binding pocket surfacesClinical and biological role of secretory phospholipase A2 in acute respiratory distress syndrome infants.Phospholipase A(2) enzymes in metabolic and cardiovascular diseases.Oral administration of cytosolic PLA2 inhibitor arachidonyl trifluoromethyl ketone ameliorates cauda equina compression injury in ratsInhibition of secreted phospholipases A₂ by 2-oxoamides based on α-amino acids: Synthesis, in vitro evaluation and molecular docking calculations.Interactions of platinum and ruthenium coordination complexes with pancreatic phospholipase A(2) and phospholipids investigated by MALDI TOF mass spectrometry.Binding conformation of 2-oxoamide inhibitors to group IVA cytosolic phospholipase A2 determined by molecular docking combined with molecular dynamics.Pharmacophore-based discovery of a novel cytosolic phospholipase A(2)α inhibitor.Calcium-independent phospholipases A2 and their roles in biological processes and diseases.Biological activity and binding properties of [Ru(II)(dcbpy)2Cl2] complex to bovine serum albumin, phospholipase A2 and glutathione.Competition and allostery govern substrate selectivity of cyclooxygenase-2.Using hydrogen/deuterium exchange mass spectrometry to define the specific interactions of the phospholipase A2 superfamily with lipid substrates, inhibitors, and membranes.Biochemical characterization of selective inhibitors of human group IIA secreted phospholipase A(2) and hyaluronic acid-linked inhibitor conjugates.Cytosolic phospholipase A2 (cPLA2) IVA as a potential signature molecule in cigarette smoke condensate induced pathologies in alveolar epithelial lineages.IRAK1/4-targeted anti-inflammatory action of caffeic acid.New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2.(S)-tetrahydroisoquinoline alkaloid inhibits LPS-induced arachidonic acid release through downregulation of cPLA2 expression.Development of a potent 2-oxoamide inhibitor of secreted phospholipase A2 guided by molecular docking calculations and molecular dynamics simulations.Phospholipase A2 and arachidonic acid in Alzheimer's diseaseHerbal medicinal products target defined biochemical and molecular mediators of inflammatory autoimmune arthritis.Towards novel radiosensitizing agents: the role of cytosolic PLA2α in combined modality cancer therapy.Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).Newer treatments in the management of pediatric asthma.Chemical modulation of glycerolipid signaling and metabolic pathways.Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016).Structural Insight into Binding Mode of 9-Hydroxy Aristolochic Acid, Diclofenac and Indomethacin to PLA2.Attenuation of cysteamine-induced duodenal ulcer with Cochinchina momordica seed extract through inhibiting cytoplasmic phospholipase A2/5-lipoxygenase and activating γ-glutamylcysteine synthetase.Suppressive effects of PG201, an antiarthritic botanical formulation, on lipopolysaccharide-induced inflammatory mediators in Raw264.7 cells.2-Oxoamide inhibitors of cytosolic group IVA phospholipase A2 with reduced lipophilicity.Phylogenetic and structural analysis of the phospholipase A2 gene family in vertebratesFluoroketone inhibition of Ca(2+)-independent phospholipase A2 through binding pocket association defined by hydrogen/deuterium exchange and molecular dynamics.Off-target effect of the cPLA2α inhibitor pyrrophenone: Inhibition of calcium release from the endoplasmic reticulumPolarization of Macrophages toward M2 Phenotype Is Favored by Reduction in iPLA2β (Group VIA Phospholipase A2)2-Oxoamides based on dipeptides as selective calcium-independent phospholipase A2 inhibitors.Discovery of novel secretory phospholipase A2 inhibitors using virtual screen.Inhibition of benzalkonium chloride-induced skin inflammation in mice by an indol-1-ylpropan-2-one inhibitor of cytosolic phospholipase A2 α.High-affinity selective inhibitor against phospholipase A2 (PLA2): a computational study.
P2860
Q23923367-9778D6F3-0BA5-463F-AF0E-00ACB24E43E2Q26997377-8C978D6C-8A1E-45DE-A6E1-B3910E20B9F0Q28538129-DA12006E-101A-4872-AFEA-C752951093F6Q33753852-A33958B1-9118-4DA3-A835-8D166B64662EQ33773427-8A977AAB-8C17-4062-9705-DF18C9A7E528Q34476283-A115E643-8DF0-42A2-BAF6-6B53AA6EFB1CQ34632021-6696C993-4138-4150-9680-2F86182A89F0Q35045281-85BBCC8A-AEAE-413B-84D7-FAF5D968F04CQ35691760-F856485C-1A3F-427B-82FA-305A5551DC7CQ35709484-3C4E4995-BB3B-4C86-848B-368A0D1469C3Q35994344-B85FEEBB-C979-46C1-8FDB-27000D1A4324Q36102249-DD7D1BA4-F631-40CB-BC8C-6C4E3AD67289Q36155103-BBC60AF4-9CC8-4D32-B4B5-96E26759AD83Q36543771-6A3724BD-F452-41C2-A497-29D5F190CACDQ36545315-2C9F5720-1723-45D4-AF5D-310239E72EDDQ37178634-03FA2C9C-00DF-4B24-A9BA-24F04E21952FQ37392910-6CC4697A-283E-4064-B4F6-5B97DBB7EE18Q37443756-4563911B-36B6-4B9B-AA97-2A9E5060CF44Q37462486-2003B6A2-7738-44ED-BC3A-15310EFE46E1Q37624745-754B76E1-4267-4980-90F5-0430947D2586Q37765687-161439BC-5C61-4428-A62A-21F8979C4E05Q37813237-413816AA-026B-46E2-8A84-C5F3258FA7B2Q37885347-6895D74D-B350-4D53-B080-1F4EB2F9FA4AQ38072094-798DA7E5-E071-4280-A56D-7C1357CD3309Q38113498-D28B4873-2AC1-4937-8B34-2D72B21B1F9DQ38179801-0212808C-A17D-4855-9EA5-54551E80B9B8Q38975723-68806207-F83E-4FDD-BDEE-261A09E43819Q39160525-D046B27F-5DF6-489D-9EF3-4AE02CD487EBQ39364183-3F52CCA0-FC70-43D0-8939-31830DBA776DQ39374982-1DEA9637-F37A-42C7-9F13-A202349BD880Q41634441-9421F56A-52DF-4E04-8DB3-759B5B1AF44CQ41645827-2FEF5000-346C-4511-BC4E-506D8CBAC21FQ42136740-D8C3C721-7CEB-42A4-AE9F-D150CD30F5AAQ42383395-A1BE0A6D-A5FF-48DE-9608-263E3477E7F3Q42725788-0B29D3F1-ED77-4969-959A-AC43EF9B7F09Q43747404-78B801FB-DD14-4B38-A3D1-AEE81E2C599AQ46921634-F546D46D-C5D4-4BF8-88C8-7F0247D74C67Q52767073-A7E28455-9C99-4D1B-B503-1B45EA4F2A7EQ53787814-8F08B4EE-73DC-44E4-A4E2-41C066A22D80
P2860
Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phospholipase A2 inhibitors as ...... ment of inflammatory diseases.
@en
Phospholipase A2 inhibitors as ...... ment of inflammatory diseases.
@nl
type
label
Phospholipase A2 inhibitors as ...... ment of inflammatory diseases.
@en
Phospholipase A2 inhibitors as ...... ment of inflammatory diseases.
@nl
prefLabel
Phospholipase A2 inhibitors as ...... ment of inflammatory diseases.
@en
Phospholipase A2 inhibitors as ...... ment of inflammatory diseases.
@nl
P2860
P1476
Phospholipase A2 inhibitors as ...... tment of inflammatory diseases
@en
P2093
George Kokotos
P2860
P356
10.1517/13543770903463905
P407
P577
2010-01-01T00:00:00Z